Funding for this research was provided by:
Zanjan University of Medical Sciences (1602001000)
Dr. Abidi Pharmaceutical Company
Received: 25 July 2022
Accepted: 11 November 2022
First Online: 17 November 2022
: The EMPA-CARD trial was conducted in accordance with the principles of the declaration of Helsinki and all subsequent revisions. The study was approved by the ethics committee of Zanjan university of Medical Sciences. Moreover, the study protocol was prospectively registered on the Iranian Registry of Clinical Trials (ExternalRef removed, Identifier: IRCT20190412043247N2). All patients provided with written informed consent prior to the recruitment.
: Not applicable.
: The authors contributing to the study have nothing relevant to disclose. Only the study authors were responsible for conducting and reporting the final contents of the trial. This study had received a non-financial funding from the Dr. Abidi Pharmaceutical Company.